ARCON: Accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: A phase I/II study by the EORTC

Jacques Bernier, Juliana Denekamp, Anamaria Rojas, Mauro Trovò, Jean Claude Horiot, Han Hamers, Paolo Antognoni, Olav Dahl, Pierre Richaud, Johannes Kaanders, Martine Van Glabbeke, M. Piérart

Research output: Contribution to journalArticlepeer-review


Background: Non small cell lung cancers (NSCLC) are rapidly proliferating tumours, which are characterized by the presence of extensive hypoxic components, especially in patients with advanced loco-regional disease. Previous studies suggest a deleterious impact of acute (perfusion- limited) hypoxia on the outcome of radiotherapy for these tumours. Aim: This pilot study was aimed at determining the feasibility and tumour response rates that can be achieved with an ARCON regime in patients with locally advanced, staged IIIA or B, NSCLC tumours. Methods: The phase I/II study included three steps: accelerated fractionation (AF) combined with carbogen (ten analysable patients), AF together with the daily administration of nicotinamide (n = 11) and AF with both carbon and nicotinamide (n = 14). Radiotherapy was based on a large daily dose per fraction (2.75 Gy up to 55 Gy in 4 weeks). Nicotinamide was administered at a dose of 6 g per patient per treatment day and carbogen was inhaled for 5 min before and during radiotherapy. Results: The incidence of grade 3 + acute toxicity during the irradiation did not exceed 10%, neither in the lung parenchyma nor in the mediastinum. No significant difference was found in loco-regional, radio- induced toxicity among the three study steps. Although a similar fraction of patients showed grade 2 or 3 emesis in all the steps, of the 25 patients entered in the two Nicotinamide containing steps 10 (40%) developed grade 2 or greater reactions which significantly detracted from their quality of life. There was no significant difference in tumour clearance rate among the three steps. The percentage of objective responses at 2 months was 60, 54 and 57% in steps 1, 2 and 3, respectively. Conclusion: The feasibility of this ARCON protocol, using 2.75 Gy doses per fraction over 4 weeks, is good as regards radiotherapy-related side effects but it appears necessary in future to reduce the dose of Nicotinamide to reduce the incidence of nausea and vomiting. There was no significant difference in time to progression among the three study steps.

Original languageEnglish
Pages (from-to)149-156
Number of pages8
JournalRadiotherapy and Oncology
Issue number2
Publication statusPublished - Aug 1 1999


  • Accelerated fractionation
  • Carbogen
  • Nicotinamide
  • Non small cell lung cancers
  • Radiotherapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology


Dive into the research topics of 'ARCON: Accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: A phase I/II study by the EORTC'. Together they form a unique fingerprint.

Cite this